

# Report of the National Cancer Institute-sponsored world and response in acute myeloid leukemia.

Journal of Clinical Oncology

8, 813-819

DOI: [10.1200/jco.1990.8.5.813](https://doi.org/10.1200/jco.1990.8.5.813)

Citation Report

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid). New England Journal of Medicine, 1991, 324, 1385-1393.  | 13.9 | 1,226     |
| 2  | Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.. Journal of Clinical Oncology, 1991, 9, 1880-1888.   | 0.8  | 47        |
| 3  | Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells. Blood, 1991, 77, 1064-1070.  | 0.6  | 13        |
| 4  | High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood, 1991, 78, 2182-2187.   | 0.6  | 93        |
| 6  | Terminal transferase expression in acute myeloid leukaemia: biology and prognosis. British Journal of Haematology, 1991, 78, 48-54.   | 1.2  | 19        |
| 7  | Monosomy 7 in multilineage and acute lymphoblastic leukaemia. British Journal of Haematology, 1991, 79, 152-155.  | 1.2  | 20        |
| 8  | Proposed Criteria for Classification of Acute Myeloid Leukemia in Dogs and Cats. Veterinary Clinical Pathology, 1991, 20, 63-82.  | 0.3  | 124       |
| 9  | Clinical significance of CD7-positive stem cell leukemia. A distinct subtype of mixed lineage leukemia. Cancer, 1991, 68, 2273-2280.  | 2.0  | 41        |
| 10 | Acute Myeloid Leukemia in Children Treated with Etoposide for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1991, 325, 1682-1687.  | 13.9 | 697       |
| 11 | Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1991, 325, 1378-1382.  | 13.9 | 15        |
| 12 | The Clinical Significance of Biological Characteristics of the Cells in Acute Myeloid Leukemia. Annual Review of Medicine, 1991, 42, 381-389.   | 5.0  | 6         |
| 13 | Megakaryocytic Leukemia and Platelet Factor 4. Leukemia and Lymphoma, 1992, 8, 327-336.   | 0.6  | 4         |
| 15 | The Prognostic Significance of Proerythroblasts in Acute Erythroleukemia. American Journal of Clinical Pathology, 1992, 98, 34-40.  | 0.4  | 43        |
| 16 | Acute Myelogenous Leukemia in the Elderly. Journal of the American Geriatrics Society, 1992, 40, 277-284.   | 1.3  | 12        |
| 17 | G-CSF Receptors on the Surface of Ph <sup>+</sup> -positive Acute Lymphoblastic Leukemia (ALL) Cells with Myeloid Surface Antigens: ALL Cells with Myeloid Antigens have Myeloid Function. Leukemia and Lymphoma, 1992, 6, 497-501. | 0.6  | 3         |
| 18 | Acute myelogenous leukemia: Current treatment and future directions. American Journal of Medicine, 1992, 92, 286-295.   | 0.6  | 35        |
| 19 | Minimally Differentiated Acute Myeloid Leukemia: A Morphologic, Cytochemical and Ultrastructural Study. Tumori, 1992, 78, 185-189.  | 0.6  | 1         |
| 20 | Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood: a Pediatric Oncology Group study.. Journal of Clinical Oncology, 1992, 10, 1419-1429.                        | 0.8  | 51        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 21 | Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer.. Journal of Clinical Oncology, 1992, 10, 1666-1673.  | 0.8 | 136       |
| 22 | False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts. Blood, 1992, 79, 2399-2403.  | 0.6 | 60        |
| 23 | Effects of granulocyte-macrophage colony-stimulating factor and interleukin 6 on the growth of leukemic blasts in suspension culture. International Journal of Cell Cloning, 1992, 10, 166-172.   | 1.6 | 4         |
| 24 | All-trans retinoic acid in acute promyelocytic leukemia: Preliminary results in Cuba. Annals of Hematology, 1992, 65, 121-123.  | 0.8 | 7         |
| 25 | The diagnosis of acute leukemia with undifferentiated or minimally differentiated blasts. Annals of Hematology, 1992, 64, 161-165.  | 0.8 | 34        |
| 26 | Lymphoid lineage-associated features in acute myeloid leukaemia: phenotypic and genotypic correlations. British Journal of Haematology, 1992, 82, 324-331.  | 1.2 | 19        |
| 27 | Differential expression of terminal transferase (TdT) in acute lymphocytic leukaemia expressing myeloid antigens and TdT positive acute myeloid leukaemia as compared to myeloid antigen negative acute lymphocytic leukaemia. British Journal of Haematology, 1993, 84, 416-422. | 1.2 | 24        |
| 28 | Classification of myeloproliferative disorders in cats using criteria proposed by the animal leukaemia study group: A retrospective study of 181 cases (1969-1992). Comparative Haematology International, 1993, 3, 125-134.  | 0.5 | 33        |
| 29 | Immunophenotyping of acute leukemia by flow cytometry. Clinical Immunology Newsletter, 1993, 13, 54-60.   | 0.1 | 6         |
| 30 | Correlation of morphological FAB classification and immunophenotyping: Value in recognition of morphological, cytochemical and immunological characteristics of mixed leukaemias. European Journal of Cancer, 1993, 29, 1167-1172.  | 1.3 | 7         |
| 31 | Frequency of clonal remission in acute myeloid leukaemia. Lancet, The, 1993, 341, 138-142.  | 6.3 | 58        |
| 32 | Chemotherapy with High-Dose Cytosine Arabinoside and Mitoxantrone for Poor-Prognosis Myeloid Leukemias. Cancer Investigation, 1993, 11, 509-516.  | 0.6 | 6         |
| 33 | Therapy-Related Acute Myelogenous Leukemia Associated with 11q23 Chromosomal Abnormalities and Topoisomerase II Inhibitors: Report of Four Additional Cases and Brief Commentary. Leukemia and Lymphoma, 1993, 11, 141-145.   | 0.6 | 24        |
| 34 | Induction Therapy for Acute Myelogenous Leukemia in Patients Over 60 Years with Intermediate-Dose Cytosine Arabinoside, Mitoxantrone and Etoposide. Leukemia and Lymphoma, 1993, 9, 211-215.  | 0.6 | 14        |
| 35 | Treatment of Relapsing and Refractory Adult Acute Myeloid Leukemia According to in vitro Clonogenic Leukemic Cell Drug Sensitivity. Leukemia and Lymphoma, 1993, 10, 67-71.   | 0.6 | 6         |
| 36 | Immunophenotyping of Acute Leukemia by Flow Cytometric Analysis: Use of CD45 and Right-Angle Light Scatter to Gate on Leukemic Blasts in Three-Color Analysis. American Journal of Clinical Pathology, 1993, 100, 534-540.  | 0.4 | 298       |
| 38 | Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood, 1993, 82, 1689-1694.   | 0.6 | 205       |
| 39 | Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood, 1994, 84, 1237-1242.  | 0.6 | 67        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 40 | Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia. <i>Blood</i> , 1994, 84, 3054-3062.   | 0.6 | 55        |
| 41 | All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study. <i>Annals of Internal Medicine</i> , 1994, 120, 278.   | 2.0 | 242       |
| 42 | Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation.. <i>Journal of Clinical Oncology</i> , 1994, 12, 2138-2145.   | 0.8 | 25        |
| 43 | Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.. <i>Journal of Clinical Oncology</i> , 1994, 12, 2193-2203.  | 0.8 | 109       |
| 44 | Evaluation of Carboplatin as a Single Agent in Highly Refractory Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1994, 15, 311-315.  | 0.6 | 5         |
| 45 | Peroxidase Expression in Acute Unclassified Leukemias: Ultrastructural Studies in Combination with Immunophenotyping. <i>Leukemia and Lymphoma</i> , 1994, 14, 103-109.   | 0.6 | 3         |
| 46 | Acute myeloid leukemia in manitoba. <i>Cancer</i> , 1994, 74, 52-60.  | 2.0 | 23        |
| 47 | SPONTANEOUS REMISSION IN ACUTE MYELOID LEUKAEMIA. <i>British Journal of Haematology</i> , 1994, 87, 880-882.  | 1.2 | 28        |
| 48 | Myelodysplasie syndrome in a Quarter Horse gelding. <i>Equine Veterinary Journal</i> , 1994, 26, 83-85.   | 0.9 | 22        |
| 49 | Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review.. <i>Journal of Clinical Oncology</i> , 1995, 13, 1800-1816.   | 0.8 | 546       |
| 50 | Extramedullary Tumors of Lymphoid or Myeloid Blasts:<i>The Role of Immunohistology in Diagnosis and Classification</i>. <i>American Journal of Clinical Pathology</i> , 1995, 104, 431-443.   | 0.4 | 44        |
| 51 | Trisomy 11: an association with stem/progenitor cell immunophenotype. <i>British Journal of Haematology</i> , 1995, 90, 266-273.  | 1.2 | 32        |
| 52 | Morphologic characteristics of erythroleukemia (Acute Myeloid Leukemia; FAB-M6): A CALGB study. <i>American Journal of Hematology</i> , 1995, 49, 29-38.  | 2.0 | 50        |
| 53 | Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. <i>Cancer</i> , 1995, 76, 1564-1570.   | 2.0 | 45        |
| 54 | Acute lymphoblastic leukemia a comprehensive review with emphasis on biology and therapy. <i>Cancer</i> , 1995, 76, 2393-2417.  | 2.0 | 126       |
| 55 | Translocation (8;21) in acute myeloid leukemia: When to treat? That is the question!!. <i>Leukemia Research</i> , 1995, 19, 357-358.  | 0.4 | 2         |
| 56 | rHuGM-CSF after high-dose chemotherapy in post-remission acute leukemia. <i>Stem Cells</i> , 1995, 13, 112-122.   | 1.4 | 4         |
| 57 | High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group. <i>Blood</i> , 1995, 85, 1391-1395. | 0.6 | 73        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 58 | A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. <i>Blood</i> , 1995, 85, 2025-2037.                   | 0.6  | 564       |
| 59 | Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. <i>Blood</i> , 1995, 86, 1717-1728.   | 0.6  | 128       |
| 60 | Treatment of Acute Promyelocytic Leukemia in Patients Presenting at Vancouver General Hospital from 1983 to 1992. <i>Leukemia and Lymphoma</i> , 1995, 16, 439-444.  | 0.6  | 1         |
| 61 | Topical Nitroglycerin Therapy for Anal Fissures and Ulcers. <i>New England Journal of Medicine</i> , 1995, 333, 1156-1157.   | 13.9 | 91        |
| 62 | Techniques for Detection of Minimal Residual Disease. <i>Leukemia and Lymphoma</i> , 1995, 18, 75-80.  | 0.6  | 9         |
| 63 | DNA Fingerprint Analysis in Acute Leukemias. <i>Leukemia and Lymphoma</i> , 1995, 17, 27-33.   | 0.6  | 1         |
| 64 | New Neuromuscular Blocking Drugs. <i>New England Journal of Medicine</i> , 1995, 333, 1155-1155.   | 13.9 | 1         |
| 65 | Recombinant Granulocyte Colony-Stimulating Factor in Acute Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 1995, 333, 1155-1156.  | 13.9 | 3         |
| 66 | Granulocyte Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 1995, 332, 1671-1677.         | 13.9 | 441       |
| 67 | A Controlled Study of Recombinant Human Granulocyte Colony-Stimulating Factor in Elderly Patients after Treatment for Acute Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 1995, 332, 1678-1683. | 13.9 | 316       |
| 68 | Otitis Media in Children. <i>New England Journal of Medicine</i> , 1995, 333, 1151-1152.   | 13.9 | 7         |
| 69 | Fluoxetine for Premenstrual Dysphoria. <i>New England Journal of Medicine</i> , 1995, 333, 1152-1153.  | 13.9 | 4         |
| 70 | Transesophageal Echocardiography. <i>New England Journal of Medicine</i> , 1995, 333, 1153-1154.   | 13.9 | 2         |
| 71 | Hypoglycemic Disorders. <i>New England Journal of Medicine</i> , 1995, 333, 1154-1155.   | 13.9 | 1         |
| 72 | Clinical Problem-Solving. <i>New England Journal of Medicine</i> , 1995, 333, 1157-1157.   | 13.9 | 1         |
| 73 | Clinical, Morphologic, Cytogenetic and Prognostic Implications of CD34 Expression in Childhood and Adult de novo AML. <i>Leukemia and Lymphoma</i> , 1995, 17, 417-426.  | 0.6  | 23        |
| 74 | Invasive Fungal Disease in Adults Undergoing Remission-Induction Therapy for Acute Myeloid Leukemia: The Pathogenetic Role of the Antileukemic Regimen. <i>Clinical Infectious Diseases</i> , 1995, 21, 361-369. | 2.9  | 190       |
| 75 | Routine bone marrow exam during first remission of acute myeloid leukemia. <i>Blood</i> , 1996, 87, 3899-3902.   | 0.6  | 16        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 76 | Granulocyte-Macrophage-Colony-Stimulating Factor Support in Patients with Acute Non-Lymphatic Leukemia. <i>Oncology</i> , 1996, 53, 482-487.   | 0.9  | 3         |
| 77 | Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2486-2494.               | 0.8  | 53        |
| 78 | Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation.. <i>Journal of Clinical Oncology</i> , 1996, 14, 1353-1363.                                    | 0.8  | 31        |
| 79 | Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 122, 307-312.  | 1.2  | 5         |
| 80 | Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: A phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group. <i>Annals of Hematology</i> , 1996, 72, 119-124. | 0.8  | 13        |
| 81 | Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia. , 1996, 51, 117-121.   |      | 9         |
| 82 | Diagnosis and treatment of acute myelogenous leukemia in childhood. <i>Critical Reviews in Oncology/Hematology</i> , 1996, 22, 183-196.  | 2.0  | 2         |
| 83 | Minimally differentiated acute myeloid leukaemia revealed by specific cutaneous lesions. <i>British Journal of Dermatology</i> , 1996, 135, 119-123.   | 1.4  | 3         |
| 84 | Phase I trials in paediatric oncology ? the European perspective. <i>Investigational New Drugs</i> , 1996, 14, 23-32.  | 1.2  | 9         |
| 85 | Value of colony forming unit-granulocyte macrophage assay in predicting relapse in acute myeloid leukaemia.. <i>Journal of Clinical Pathology</i> , 1996, 49, 450-452.   | 1.0  | 5         |
| 86 | Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease.. <i>Journal of Clinical Pathology</i> , 1996, 49, 15-18.   | 1.0  | 60        |
| 87 | Acute Myeloid Leukemia with Translocation (8;21). Cytomorphology, Dysplasia and Prognostic Factors in 41 Cases. <i>Leukemia and Lymphoma</i> , 1996, 23, 227-234.  | 0.6  | 48        |
| 88 | Hematopoietic growth factor (G-CSF or GM-CSF) after salvage chemotherapy in refractory or relapsed adult de novo acute leukemia. <i>Leukemia and Lymphoma</i> , 1996, 20, 321-326.   | 0.6  | 3         |
| 89 | Useful Panel of Antibodies for the Classification of Acute Leukemia by Immunohistochemical Methods in Bone Marrow Trepine Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 1997, 107, 410-418.  | 0.4  | 51        |
| 91 | Flow Cytometry: Recent Advances in Diagnosis and Monitoring of Leukemia. <i>Cancer Investigation</i> , 1997, 15, 384-399.  | 0.6  | 24        |
| 92 | All-trans-Retinoic Acid in Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 1997, 337, 1021-1028.  | 13.9 | 1,006     |
| 93 | DIAGNOSIS AND TREATMENT OF CHILDHOOD ACUTE MYELOGENOUS LEUKEMIA. <i>Pediatric Clinics of North America</i> , 1997, 44, 847-862.  | 0.9  | 18        |
| 94 | Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2254-2261.   | 0.8  | 99        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 95  | Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy.. Journal of Clinical Oncology, 1997, 15, 2262-2268.   | 0.8 | 39        |
| 96  | Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.. Journal of Clinical Oncology, 1997, 15, 466-475.                                     | 0.8 | 215       |
| 97  | Induction Failure in <i>de novo</i> Acute Myelogenous Leukemia is Associated with Expression of High Levels of CD34 Antigen by the Leukemic Blasts. Leukemia and Lymphoma, 1997, 26, 299-306.  | 0.6 | 9         |
| 98  | Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study. Blood, 1997, 89, 3323-3329.              | 0.6 | 799       |
| 99  | Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood, 1997, 89, 780-788. | 0.6 | 101       |
| 100 | Stem Cell Transplantation for Secondary Acute Myeloid Leukemia: Evaluation of Transplantation as Initial Therapy or Following Induction Chemotherapy. Blood, 1997, 89, 2578-2585.  | 0.6 | 151       |
| 101 | Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22). Blood, 1997, 90, 1643-1648.   | 0.6 | 218       |
| 102 | Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients. Blood, 1997, 90, 2465-2470.  | 0.6 | 241       |
| 103 | Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy. Blood, 1997, 90, 2863-2892.   | 0.6 | 390       |
| 104 | Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in) Tj ETQq1 1 0.784314 rgBT /Over 1997, 90, 2969-2977.  | 0.6 | 218       |
| 105 | Contribution of oncogenes and tumor suppressor genes to myeloid leukemia. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1332, F67-F104.  | 3.3 | 12        |
| 106 | Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics. Annals of Hematology, 1997, 75, 81-86.   | 0.8 | 12        |
| 107 | Adult acute leukemia. Current Problems in Cancer, 1997, 21, 1-64.  | 1.0 | 24        |
| 108 | Hematological features and treatment outcome in acute myeloid leukemia with t(8;21). , 1997, 15, 93-103.   |     | 10        |
| 109 | Comparative utility of diagnostic bone-marrow components: A 10-year study. , 1997, 56, 37-41.  |     | 22        |
| 110 | Geographical considerations regarding donor leukocyte infusions for the treatment of relapsed hematological malignancies. , 1998, 17, 249-257.   |     | 3         |
| 111 | An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B. Leukemia, 1998, 12, 139-143. | 3.3 | 13        |
| 112 | Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia, 1998, 12, 317-325.  | 3.3 | 78        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 113 | Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. <i>Leukemia</i> , 1998, 12, 660-665.   | 3.3  | 81        |
| 114 | Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. <i>Leukemia</i> , 1998, 12, 1482-1489.   | 3.3  | 157       |
| 115 | Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin. <i>Cancer</i> , 1998, 83, 1344-1354.  | 2.0  | 8         |
| 116 | Diagnostik und Therapie der akuten myeloischen Leukämien (AML). <i>Onkologe</i> , 1998, 4, 791-797.  | 0.7  | 1         |
| 117 | The clinical significance of detection of residual disease in childhood ALL. <i>Critical Reviews in Oncology/Hematology</i> , 1998, 28, 31-55.   | 2.0  | 15        |
| 118 | Repeated Cycles of G-CSF Combined Postremission Chemotherapy for Acute Myeloid Leukemia in a First Complete Remission: A Pilot Study. <i>Stem Cells</i> , 1998, 16, 280-287.   | 1.4  | 2         |
| 119 | Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1998, 103, 1096-1103.  | 1.2  | 66        |
| 120 | Myeloperoxidase Gene Expression in Infant Leukemia: A Pediatric Oncology Group Study. <i>Leukemia and Lymphoma</i> , 1998, 29, 145-160.  | 0.6  | 11        |
| 121 | Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 1998, 339, 1649-1656.   | 13.9 | 569       |
| 122 | A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia. <i>Leukemia and Lymphoma</i> , 1998, 31, 343-349.   | 0.6  | 49        |
| 123 | Prevalence of Myeloperoxidase Gene Expression in Infant Acute Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 1998, 110, 575-581.  | 0.4  | 21        |
| 124 | Familial Erythroleukemia: A Distinct Clinical and Genetic Type of Familial Leukemias. <i>Leukemia and Lymphoma</i> , 1998, 30, 395-401.  | 0.6  | 12        |
| 125 | Conduct of phase I trials in children with cancer.. <i>Journal of Clinical Oncology</i> , 1998, 16, 966-978.   | 0.8  | 93        |
| 126 | A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031). <i>Blood</i> , 1998, 91, 3607-3615.  | 0.6  | 285       |
| 127 | Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 1910-1917.   | 0.6  | 147       |
| 128 | Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420. <i>Journal of Clinical Oncology</i> , 1999, 17, 2831-2831. | 0.8  | 83        |
| 129 | CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome?. <i>Journal of Clinical Oncology</i> , 1999, 17, 293-293.   | 0.8  | 114       |
| 130 | Diagnosis of Childhood Acute Myeloid Leukemia. <i>Clinics in Laboratory Medicine</i> , 1999, 19, 187-238.  | 0.7  | 12        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 131 | Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar). <i>Blood</i> , 1999, 93, 787-795.   | 0.6 | 141       |
| 132 | Double Immunoenzymatic APAAP Staining for the Detection of Leukemia-Associated Immunophenotypes. <i>Journal of Hematotherapy and Stem Cell Research</i> , 1999, 8, 635-643.  | 1.8 | 3         |
| 133 | Definition of a standard-risk group in children with AML. <i>British Journal of Haematology</i> , 1999, 104, 630-639.  | 1.2 | 122       |
| 134 | Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 1999, 105, 775-779.   | 1.2 | 55        |
| 135 | A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. <i>British Journal of Haematology</i> , 1999, 106, 1027-1032.  | 1.2 | 100       |
| 136 | A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. <i>British Journal of Haematology</i> , 1999, 107, 69-79.                               | 1.2 | 376       |
| 137 | Acute leukaemia immunophenotyping in bone-marrow routine sections. <i>British Journal of Haematology</i> , 1999, 105, 394-401.   | 1.2 | 51        |
| 138 | Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study. <i>Leukemia</i> , 1999, 13, 343-347.   | 3.3 | 34        |
| 139 | Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. <i>Leukemia</i> , 1999, 13, 376-385.  | 3.3 | 142       |
| 140 | Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. <i>Leukemia</i> , 1999, 13, 1175-1187.   | 3.3 | 35        |
| 141 | Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. <i>Oncogene</i> , 1999, 18, 3159-3165.   | 2.6 | 54        |
| 142 | Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. <i>Bone Marrow Transplantation</i> , 1999, 24, 467-472. | 1.3 | 40        |
| 143 | Cryptic <i>Mucor</i> infection leading to massive cerebral infarction at initiation of antileukemic chemotherapy. <i>Annals of Hematology</i> , 1999, 78, 241-245.   | 0.8 | 22        |
| 144 | Polyclonal hypergammaglobulinemia at the onset of acute myeloid leukemia in children. <i>Annals of Hematology</i> , 1999, 78, 445-448.   | 0.8 | 2         |
| 145 | Acute Myeloblastic Leukemia (M0) with an Unusual Chromosomal Abnormality. <i>Cancer Genetics and Cytogenetics</i> , 1999, 111, 175-177.  | 1.0 | 4         |
| 146 | Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia. , 1999, 85, 358-367.  |     | 35        |
| 147 | A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. <i>Cancer</i> , 1999, 85, 1506-1513.  | 2.0 | 53        |
| 148 | An abnormal CD34+myeloid/CD34+lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia. , 1999, 38, 70-75.   |     | 9         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 149 | Uncommon patterns of presentation of leukemia. , 1999, 17, 11-29.   |     | 10        |
| 150 | Potential use of serum CD44 as an indicator of tumour progression in acute leukemia. , 1999, 17, 161-168.   |     | 15        |
| 151 | Development and Validation of a Quantitative Polymerase Chain Reaction Assay to Evaluate Minimal Residual Disease for T-Cell Acute Lymphoblastic Leukemia and Follicular Lymphoma. American Journal of Pathology, 1999, 154, 1023-1035.                   | 1.9 | 20        |
| 152 | Use of Peripheral Blood Blasts <i>vs</i> Bone Marrow Blasts for Diagnosis of Acute Leukemia. American Journal of Clinical Pathology, 1999, 111, 733-740.  | 0.4 | 41        |
| 153 | Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 1999, 17, 1244-1244.  | 0.8 | 3,209     |
| 154 | Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered. Journal of Clinical Oncology, 1999, 17, 3767-3775.                             | 0.8 | 290       |
| 155 | Modified intranuclear organization of regulatory factors in human acute leukemias: Reversal after treatment. , 2000, 77, 30-43.   |     | 10        |
| 156 | Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases. American Journal of Hematology, 2000, 65, 5-13.   | 2.0 | 52        |
| 157 | Flow cytometric assessment of CD15+CD117+ cells for the detection of minimal residual disease in adult acute myeloid leukaemia. British Journal of Haematology, 2000, 108, 710-716.   | 1.2 | 21        |
| 158 | Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells. Leukemia, 2000, 14, 412-418.  | 3.3 | 24        |
| 159 | An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia, 2000, 14, 786-791.  | 3.3 | 66        |
| 160 | High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia, 2000, 14, 1191-1196.                             | 3.3 | 15        |
| 161 | A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617. Leukemia Research, 2000, 24, 567-574. | 0.4 | 58        |
| 162 | Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia. Leukemia Research, 2000, 24, 871-875.   | 0.4 | 25        |
| 163 | Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. Leukemia Research, 2000, 24, 957-963.  | 0.4 | 10        |
| 164 | A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. Leukemia Research, 2000, 24, 183-187.  | 0.4 | 20        |
| 165 | Erythroblastic and/or megakaryocytic dysplasia in de novo acute myeloid leukemias M0-M5 show relation to myelodysplastic syndromes and delimit two main categories. Leukemia Research, 2000, 24, 207-215.   | 0.4 | 11        |
| 166 | Analysis of thrombopoietin receptor (c-mpl) mRNA expression in de novo acute myeloid leukemia. Leukemia Research, 2000, 24, 401-409.  | 0.4 | 10        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 167 | Therapy for childhood acute myeloid leukemia: Role of allogeneic bone marrow transplantation. <i>Current Oncology Reports</i> , 2000, 2, 529-538.   | 1.8 | 7         |
| 168 | Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. <i>Annals of Hematology</i> , 2000, 79, 501-506.  | 0.8 | 89        |
| 169 | In vitro effect of multidrug resistance modifiers on idarubicin efflux in blasts of acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2000, 126, 111-116.   | 1.2 | 9         |
| 170 | Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. <i>Blood</i> , 2000, 95, 72-77.  | 0.6 | 97        |
| 171 | Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. <i>Blood</i> , 2000, 95, 2637-2644.  | 0.6 | 433       |
| 172 | Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. <i>Blood</i> , 2000, 96, 3948-3952.   | 0.6 | 225       |
| 173 | Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. <i>Blood</i> , 2000, 96, 4075-4083.              | 0.6 | 1,442     |
| 174 | Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2000, 18, 1867-1875.   | 0.8 | 48        |
| 175 | CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy. <i>Journal of Clinical Oncology</i> , 2000, 18, 1295-1300. | 0.8 | 156       |
| 176 | Special Stains in the Diagnosis of Acute Leukemia. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 29-38.   | 0.7 | 3         |
| 177 | Response criteria for NHL: Importance of "normal" lymph node size and correlations with response rates. <i>Annals of Oncology</i> , 2000, 11, 399-408.  | 0.6 | 62        |
| 178 | Diagnostic Flow Cytometry in Hematologic Malignancies. , 2001, 55, 179-215.   |     | 1         |
| 179 | Induction of Differentiation and Apoptosis" A Possible Strategy in the Treatment of Adult Acute Myelogenous Leukemia. <i>Oncologist</i> , 2000, 5, 454-462.   | 1.9 | 40        |
| 180 | Cyclophosphamide, Ara-C and Topotecan (CAT) for Patients With Refractory or Relapsed Acute Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 36, 479-484.  | 0.6 | 35        |
| 181 | Clinical significance of minimal residual disease in leukemia.. <i>International Journal of Oncology</i> , 2000, 17, 1277-87.   | 1.4 | 4         |
| 182 | Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma. <i>Current Pharmaceutical Biotechnology</i> , 2000, 1, 1-9.   | 0.9 | 122       |
| 183 | Toxicity and effectivity of high-dose Idarubicin during AML induction therapy: Results of a pilot study in children. <i>Klinische Padiatrie</i> , 2000, 212, 163-168.   | 0.2 | 15        |
| 184 | A Pilot Study of Busulfan, Cyclophosphamide and Etoposide Followed by Autologous Transplantation for Acute Myeloid Leukemia in Remission. <i>Acta Haematologica</i> , 2000, 104, 144-147.   | 0.7 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 185 | Optimal two-stage designs for phase ii clinical trials with differentiation of complete and partial responses. <i>Communications in Statistics - Theory and Methods</i> , 2000, 29, 923-940.  | 0.6 | 18        |
| 186 | New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction-Present Use and Future Possibilities. <i>Stem Cells</i> , 2000, 18, 157-165.  | 1.4 | 61        |
| 187 | Treatment of acute myeloid leukaemia in younger patients. <i>Best Practice and Research in Clinical Haematology</i> , 2001, 14, 95-118.   | 0.7 | 9         |
| 188 | Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978. <i>European Journal of Cancer</i> , 2001, 37, 695-702.  | 1.3 | 16        |
| 189 | Flow cytometry in the diagnosis of acute leukemia. <i>Seminars in Hematology</i> , 2001, 38, 124-138.   | 1.8 | 119       |
| 190 | Leucemias agudas mieloides. Manifestaciones clínicas, diagnóstico, pronóstico y estrategias terapéuticas. <i>Medicine</i> , 2001, 8, 2890-2896.   | 0.0 | 0         |
| 191 | First Line Therapy with Fludarabine Combinations in 42 Patients with Either Post Myelodysplastic Syndrome or Therapy Related Acute Myeloid Leukaemia. <i>Leukemia and Lymphoma</i> , 2001, 40, 305-313.   | 0.6 | 23        |
| 192 | Acute Myeloid Leukemia in the Setting of Low Dose Weekly Methotrexate Therapy for Rheumatoid Arthritis. <i>Leukemia and Lymphoma</i> , 2001, 42, 371-378.   | 0.6 | 12        |
| 193 | Glutathione S-Transferase Polymorphisms and Outcome of Chemotherapy in Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 1279-1287.   | 0.8 | 139       |
| 194 | Extramedullary Involvement at Relapse in Acute Promyelocytic Leukemia Patients Treated or Not With All-Trans Retinoic Acid: A Report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. <i>Journal of Clinical Oncology</i> , 2001, 19, 4023-4028.                           | 0.8 | 135       |
| 195 | Improved Treatment Results in High-Risk Pediatric Acute Myeloid Leukemia Patients After Intensification With High-Dose Cytarabine and Mitoxantrone: Results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. <i>Journal of Clinical Oncology</i> , 2001, 19, 2705-2713. | 0.8 | 183       |
| 196 | Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 1589-1599.  | 0.8 | 76        |
| 197 | Disorders of Bone Marrow. , 2001, , 125-161.  |     | 2         |
| 198 | Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. <i>Blood</i> , 2001, 97, 3226-3233.  | 0.6 | 91        |
| 199 | The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. <i>Blood</i> , 2001, 98, 1312-1320.                              | 0.6 | 849       |
| 200 | Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. <i>Blood</i> , 2001, 97, 3361-3369.  | 0.6 | 445       |
| 201 | High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). <i>Blood</i> , 2001, 97, 3574-3580.   | 0.6 | 188       |
| 202 | Criteria for the diagnosis of acute megakaryocytic leukemia. <i>Blood</i> , 2001, 97, 1898-1898.  | 0.6 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 203 | T-cell apoptosis in HIV-1 infected individuals receiving highly active antiretroviral therapy. <i>Blood</i> , 2001, 97, 1898-1901.  | 0.6 | 6         |
| 204 | Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. <i>Blood</i> , 2001, 98, 241-243.   | 0.6 | 131       |
| 205 | Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. <i>Blood</i> , 2001, 98, 3212-3220.  | 0.6 | 393       |
| 206 | Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. <i>Blood</i> , 2001, 98, 548-553.  | 0.6 | 197       |
| 207 | Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. <i>Blood</i> , 2001, 98, 1302-1311.   | 0.6 | 415       |
| 208 | Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. <i>Blood</i> , 2001, 98, 1746-1751.  | 0.6 | 316       |
| 209 | The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. <i>Blood</i> , 2001, 98, 1752-1759. | 0.6 | 1,392     |
| 210 | Prognostic significance of minimal residual disease detection and PML/RAR- $\hat{\pm}$ isoform type: long-term follow-up in acute promyelocytic leukemia. <i>Blood</i> , 2001, 98, 2651-2656.   | 0.6 | 90        |
| 211 | 6-Mercaptopurine, Still Valuable for the Palliative Treatment of Acute Myeloid Leukaemia. <i>Hematology</i> , 2001, 6, 231-240.   | 0.7 | 2         |
| 212 | Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia. <i>Advances in Therapy</i> , 2001, 18, 67-74.   | 1.3 | 2         |
| 213 | Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2001, 112, 308-314.   | 1.2 | 67        |
| 214 | Acute myeloid leukaemia in human immunodeficiency virus-infected adults: epidemiology, treatment feasibility and outcome. <i>British Journal of Haematology</i> , 2001, 112, 900-908.   | 1.2 | 51        |
| 215 | Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. <i>Leukemia Research</i> , 2001, 25, 473-482.   | 0.4 | 41        |
| 216 | High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. <i>Cancer</i> , 2001, 92, 7-14.   | 2.0 | 46        |
| 217 | High-dose chemotherapy in high-risk myelodysplastic syndrome. <i>Cancer</i> , 2001, 92, 1999-2015.  | 2.0 | 88        |
| 218 | Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and Tj ETQq1 1 0,784314 rgBT /Overl<br>23-27.   | 2.0 | FO        |
| 219 | Oral Etoposide in Patients with Hematological Malignancies. <i>Medical Oncology</i> , 2001, 18, 269-276.  | 1.2 | 9         |
| 220 | Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution. <i>Bone Marrow Transplantation</i> , 2001, 27, 1045-1052.  | 1.3 | 8         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 221 | HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. <i>Leukemia</i> , 2001, 15, 128-133.  | 3.3 | 57        |
| 222 | Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. <i>Leukemia</i> , 2001, 15, 348-354.  | 3.3 | 134       |
| 223 | Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. <i>Leukemia</i> , 2001, 15, 764-771.  | 3.3 | 35        |
| 227 | Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2001, 27, 829-835.   | 1.3 | 7         |
| 228 | Acute Leukemia during Pregnancy: A Single Institutional Experience with 17 Cases. <i>Leukemia and Lymphoma</i> , 2001, 41, 571-577.  | 0.6 | 86        |
| 229 | Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). <i>Blood</i> , 2002, 100, 4325-4336. | 0.6 | 1,444     |
| 230 | Treatment of Refractory Acute Leukemia with Timed Sequential Chemotherapy Using Topotecan Followed by Etoposide+Mitoxantrone (T-EM) and Correlation with Topoisomerase II Levels. <i>Leukemia and Lymphoma</i> , 2002, 43, 989-999.  | 0.6 | 14        |
| 231 | Clinical Relevance of Minimal Residual Disease Detection in Adult Acute Myeloid Leukemia. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 349-357.  | 1.8 | 21        |
| 232 | A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. <i>Blood</i> , 2002, 99, 3517-3523.  | 0.6 | 170       |
| 233 | Treatment of refractory and relapsed acute myelogenous leukemia. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 287-295.  | 1.1 | 16        |
| 234 | Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). <i>Blood</i> , 2002, 100, 2717-2723.  | 0.6 | 476       |
| 235 | Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. <i>International Journal of Oncology</i> , 2002, 21, 1041.  | 1.4 | 15        |
| 236 | The Immunophenotype of 325 Adult Acute Leukemias. <i>American Journal of Clinical Pathology</i> , 2002, 117, 380-389.  | 0.4 | 74        |
| 237 | Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. <i>Leukemia</i> , 2002, 16, 581-586.                                   | 3.3 | 21        |
| 238 | Phase I Evaluation of Prolonged-Infusion Gemcitabine With Mitoxantrone for Relapsed or Refractory Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 674-679.   | 0.8 | 23        |
| 239 | Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. <i>Blood</i> , 2002, 99, 252-257.   | 0.6 | 158       |
| 240 | Efficacy and safety of thalidomide in patients with acute myeloid leukemia. <i>Blood</i> , 2002, 99, 834-839.  | 0.6 | 92        |
| 241 | Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. <i>Blood</i> , 2002, 99, 1943-1951.  | 0.6 | 217       |

| #   | ARTICLE   | IF    | CITATIONS |
|-----|---|-------|-----------|
| 242 | Negative prognostic value of glutathione S-transferase(GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002, 100, 2703-2707.   | 0.6   | 110       |
| 243 | A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. <i>Blood</i> , 2002, 100, 1965-1971.   | 0.6   | 534       |
| 244 | Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. <i>Blood</i> , 2002, 100, 3869-3876.   | 0.6   | 170       |
| 245 | All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. <i>Blood</i> , 2002, 100, 4298-4302.   | 0.6   | 427       |
| 246 | Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. <i>Blood</i> , 2002, 100, 4372-4380.   | 0.6   | 794       |
| 247 | Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia Study Group Ulm. <i>Journal of Clinical Oncology</i> , 2002, 20, 3254-3261.                | 0.8   | 291       |
| 248 | Acute Promyelocytic Leukemia M3: Cytomorphologic, Immunophenotypic, Cytogenetic, and Molecular Variants. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 941-950.  | 1.8   | 27        |
| 249 | Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. <i>Blood</i> , 2002, 100, 1224-1232.  | 0.6   | 335       |
| 250 | Phase I Evaluation of Prolonged-Infusion Gemcitabine With Mitoxantrone for Relapsed or Refractory Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 674-679.  | 0.8   | 36        |
| 251 | The Difficult Problem of Acute Myeloid Leukemia in the Older Adult. <i>Ca-A Cancer Journal for Clinicians</i> , 2002, 52, 363-371.  | 157.7 | 88        |
| 252 | Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. <i>Experimental Hematology</i> , 2002, 30, 1302-1308. | 0.2   | 35        |
| 253 | Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy. <i>Cancer</i> , 2002, 95, 1064-1070.  | 2.0   | 5         |
| 254 | Intensified Daunorubicin in Induction Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Postremission Therapy (Double-7 Protocol) for Adult Acute Myeloid Leukemia. <i>International Journal of Hematology</i> , 2002, 76, 436-445.  | 0.7   | 7         |
| 256 | Magnetic resonance imaging of femoral marrow predicts outcome in adult patients with acute myeloid leukaemia in complete remission. <i>British Journal of Haematology</i> , 2002, 117, 70-75.   | 1.2   | 11        |
| 257 | Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. <i>British Journal of Haematology</i> , 2002, 117, 869-874.   | 1.2   | 16        |
| 258 | Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. <i>Leukemia</i> , 2002, 16, 1302-1310.  | 3.3   | 181       |
| 259 | Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. <i>Leukemia</i> , 2002, 16, 1699-1704.  | 3.3   | 111       |
| 260 | Childhood leukaemia in Costa Rica, 1981-96. <i>Paediatric and Perinatal Epidemiology</i> , 2002, 16, 210-218.   | 0.8   | 26        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 261 | Analysis of MYH Tyr165Cys and Gly382Asp variants in childhood leukemias. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003, 129, 604-605.  | 1.2 | 7         |
| 262 | A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). <i>European Journal of Haematology</i> , 2003, 71, 155-162. | 1.1 | 52        |
| 263 | A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. <i>Cancer</i> , 2003, 97, 1234-1241.                              | 2.0 | 50        |
| 264 | Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. <i>Cancer</i> , 2003, 97, 2760-2766.  | 2.0 | 107       |
| 265 | CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia. <i>American Journal of Hematology</i> , 2003, 73, 149-153.  | 2.0 | 35        |
| 266 | Expression of sorcin predicts poor outcome in acute myeloid leukemia. <i>Leukemia Research</i> , 2003, 27, 125-131.   | 0.4 | 43        |
| 267 | Expression of bone morphogenetic proteins in acute promyelocytic leukemia before and after combined all trans-retinoic acid and cytotoxic treatment. <i>Leukemia Research</i> , 2003, 27, 731-738.  | 0.4 | 16        |
| 268 | Empirical examination of the neutrophil criterion ( $>1500 \times 10^9/l$ ) currently needed to declare CR in AML. <i>Leukemia Research</i> , 2003, 27, 475-479.  | 0.4 | 6         |
| 269 | Successful treatment of primary refractory acute myeloid leukemia with megadose stem cell transplantation, bone marrow boost and reduced intensity conditioning avoiding chronic graft vs. host disease and severe late toxicity. <i>Pediatric Transplantation</i> , 2003, 7, 494-496.                            | 0.5 | 9         |
| 270 | Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival. <i>British Journal of Haematology</i> , 2003, 123, 72-80.   | 1.2 | 12        |
| 271 | Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. <i>Leukemia</i> , 2003, 17, 76-82.   | 3.3 | 99        |
| 272 | High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. <i>Leukemia</i> , 2003, 17, 68-75.   | 3.3 | 63        |
| 273 | HLA-DR antigen-negative acute myeloid leukemia. <i>Leukemia</i> , 2003, 17, 707-715.  | 3.3 | 56        |
| 274 | Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial. <i>Leukemia</i> , 2003, 17, 1521-1528.  | 3.3 | 110       |
| 275 | Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. <i>Leukemia</i> , 2003, 17, 2122-2129.   | 3.3 | 98        |
| 276 | Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. <i>Leukemia</i> , 2003, 17, 2178-2182.  | 3.3 | 67        |
| 278 | Receptor induction and targeted drug delivery: a new antileukaemia strategy. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 563-574.  | 1.4 | 33        |
| 279 | Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4642-4649.  | 0.8 | 2,425     |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 280 | Classification of acute leukemias. <i>Seminars in Diagnostic Pathology</i> , 2003, 20, 142-153.  | 1.0 | 41        |
| 281 | Grupos de riesgo citogenético en la leucemia mieloide aguda: comparación de los modelos adoptados por los grupos MRC (Medical Research Council, del Reino Unido) y SWOG (Southwest Oncology) Tj ETQq1 1 0.7843.34 rgBT iOverloc  | 0.8 | 10        |
| 282 | Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. <i>Journal of Clinical Oncology</i> , 2003, 21, 1195-1204.   | 0.8 | 298       |
| 283 | Interleukin-2 After Autologous Stem-Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission. <i>Journal of Clinical Oncology</i> , 2003, 21, 615-623.  | 0.8 | 36        |
| 284 | Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 2326-2334.  | 0.8 | 146       |
| 285 | ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of acute myeloblastic leukaemia (AML) in adult patients. <i>Annals of Oncology</i> , 2003, 14, 1161-1162.   | 0.6 | 6         |
| 286 | Thalidomide for the Treatment of Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 1489-1493.   | 0.6 | 20        |
| 287 | Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. <i>Blood</i> , 2003, 101, 425-432.   | 0.6 | 221       |
| 288 | Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. <i>Blood</i> , 2003, 102, 462-469.   | 0.6 | 175       |
| 289 | Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies. <i>Journal of Clinical Oncology</i> , 2003, 21, 256-265. | 0.8 | 166       |
| 290 | Urokinase Plasminogen Activator Receptor and Soluble Matrix Metalloproteinase-9 in Acute Myeloid Leukemia Patients: A Possible Relation to Disease Invasion. <i>Hematology</i> , 2003, 8, 385-391.   | 0.7 | 23        |
| 292 | Circulating Blasts Following Chemotherapy in Pediatric Patients: Implications for Complete Remission Definition in Acute Leukemia. <i>Hematology</i> , 2003, 8, 295-301.   | 0.7 | 1         |
| 293 | Acute Promyelocytic Leukemia: A Case-based Review. <i>Hematology</i> , 2003, 8, 105-113.   | 0.7 | 2         |
| 294 | A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. <i>Blood</i> , 2003, 102, 2763-2767.  | 0.6 | 262       |
| 295 | FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. <i>Blood</i> , 2003, 102, 2387-2394.   | 0.6 | 214       |
| 296 | BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. <i>Blood</i> , 2003, 102, 1613-1618.  | 0.6 | 222       |
| 297 | Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. <i>Blood</i> , 2003, 102, 3097-3099.   | 0.6 | 17        |
| 298 | Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. <i>Blood</i> , 2003, 103, 1237-1243.   | 0.6 | 395       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 300 | Acute myeloid leukemia in elderly patients: experience of a single center. Brazilian Journal of Medical and Biological Research, 2003, 36, 703-708.   | 0.7 | 13        |
| 301 | Management of Acute Myelogenous Leukemia in the Elderly. Cancer Control, 2003, 10, 469-477.   | 0.7 | 19        |
| 302 | Haematologic Cancers. , 0, , 141-148.   |     | 0         |
| 303 | The Incidence and Survival of Acute De Novo Leukaemias in Estonia and in a Well Defined Region of Western Sweden During 1982-1996: A Survey of Patients Aged 16-64 Years. Leukemia and Lymphoma, 7 2004, 45, 915-921.   |     | 7         |
| 304 | Hematopoietic Recovery Following Induction Therapy of Acute Leukemias: Prognostic Implications and a New Look at the Definition of Remission. Leukemia and Lymphoma, 2004, 45, 67-71.   | 0.6 | 13        |
| 305 | Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98. Journal of Clinical Oncology, 2004, 22, 4384-4393.   | 0.8 | 230       |
| 306 | Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias. Clinical Cancer Research, 2004, 10, 3577-3585.  | 3.2 | 183       |
| 307 | Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621. Journal of Clinical Oncology, 2004, 22, 4290-4301. | 0.8 | 145       |
| 308 | Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2004, 22, 3432-3433.  | 0.8 | 1,712     |
| 309 | Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia. Cancer Research, 2004, 64, 5225-5231.   | 0.4 | 88        |
| 310 | Relevance of Pathologic Classifications and Diagnosis of Acute Myeloid Leukemia to Clinical Trials and Clinical Practice. , 2004, 121, 45-67.   |     | 15        |
| 311 | Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. Journal of Clinical Oncology, 2004, 22, 1087-1094.  | 0.8 | 190       |
| 312 | Elevated S-Phase Kinase-Associated Protein 2 Protein Expression in Acute Myelogenous Leukemia. Clinical Cancer Research, 2004, 10, 5123-5130.   | 3.2 | 35        |
| 313 | Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461. Journal of Clinical Oncology, 2004, 22, 2410-2418.  | 0.8 | 101       |
| 314 | Gemtuzumab ozogamicin (Mylotarg™) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Annals of Oncology, 2004, 15, 1231-1236.  | 0.6 | 24        |
| 315 | Elevated levels of transferrin receptor 2 mRNA, not transferrin receptor 1 mRNA, are associated with increased survival in acute myeloid leukaemia. British Journal of Haematology, 2004, 125, 42-49.   | 1.2 | 36        |
| 316 | The incidence and survival of acute de novo leukaemias in Estonia and in a well-defined region of western Sweden during 1982-1996: a survey of patients aged >=65 years. Journal of Internal Medicine, 2004, 256, 79-85.  | 2.7 | 7         |
| 317 | Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution. Bone Marrow Transplantation, 2004, 33, 177-182.  | 1.3 | 12        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 318 | Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. <i>Bone Marrow Transplantation</i> , 2004, 33, 891-900.  | 1.3 | 25        |
| 319 | MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. <i>Leukemia</i> , 2004, 18, 1380-1390.   | 3.3 | 162       |
| 320 | Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. <i>Leukemia</i> , 2004, 18, 1798-1803.   | 3.3 | 163       |
| 321 | Acute myeloid leukemia. <i>Apollo Medicine</i> , 2004, 1, 148-155.  | 0.0 | 0         |
| 322 | Adult acute myeloid leukaemia. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 197-222.  | 2.0 | 144       |
| 323 | Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution's experience. <i>Annals of Hematology</i> , 2004, 83, 218-224.                                      | 0.8 | 13        |
| 324 | Risk-adapted induction and consolidation therapy in adults with de novo AML aged $\geq 60\frac{1}{2}$ years: results of a prospective multicenter trial. <i>Annals of Hematology</i> , 2004, 83, 336-344.                               | 0.8 | 54        |
| 325 | Acute basophilic leukemia: Case report. <i>American Journal of Hematology</i> , 2004, 76, 134-138.  | 2.0 | 16        |
| 326 | The benefit of induction chemotherapy in patients age $\geq 75$ years. <i>Cancer</i> , 2004, 101, 325-331.  | 2.0 | 60        |
| 327 | Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. <i>Cancer</i> , 2004, 101, 1414-1419.   | 2.0 | 13        |
| 328 | Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia. <i>Leukemia Research</i> , 2004, 28, 449-455.                                  | 0.4 | 8         |
| 329 | Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. <i>Leukemia Research</i> , 2004, 28, 909-919.                           | 0.4 | 60        |
| 330 | Clinical and Biological Significance of CD56 Antigen Expression in Acute Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 1783-1789.  | 0.6 | 40        |
| 331 | CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations. <i>Journal of Clinical Oncology</i> , 2004, 22, 624-633.                             | 0.8 | 427       |
| 332 | Strategies and Clinical Implications of Chimerism Diagnostics after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2004, 112, 16-23.   | 0.7 | 57        |
| 333 | Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. <i>Blood</i> , 2004, 103, 4036-4042.  | 0.6 | 96        |
| 334 | Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. <i>Blood</i> , 2004, 104, 2467-2474. | 0.6 | 78        |
| 335 | A phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. <i>Blood</i> , 2004, 105, 959-967.  | 0.6 | 371       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 336 | A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. <i>Blood</i> , 2005, 105, 986-993.  | 0.6 | 481       |
| 337 | GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. <i>Blood</i> , 2005, 106, 447-453.  | 0.6 | 196       |
| 338 | Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. <i>Blood</i> , 2005, 105, 3420-3427. | 0.6 | 125       |
| 339 | The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. <i>Blood</i> , 2005, 106, 2646-2654. | 0.6 | 161       |
| 340 | Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. <i>Leukemia Research</i> , 2005, 29, 53-57.   | 0.4 | 73        |
| 341 | A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. <i>Leukemia Research</i> , 2005, 29, 263-271.                                      | 0.4 | 23        |
| 342 | Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. <i>Leukemia Research</i> , 2005, 29, 527-533.   | 0.4 | 34        |
| 343 | High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. <i>Leukemia Research</i> , 2005, 29, 609-615.   | 0.4 | 18        |
| 344 | Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. <i>Leukemia Research</i> , 2005, 29, 1049-1058.   | 0.4 | 123       |
| 345 | Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients. <i>Leukemia Research</i> , 2005, 29, 1109-1116.   | 0.4 | 43        |
| 346 | Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. <i>British Journal of Haematology</i> , 2005, 128, 184-191.   | 1.2 | 58        |
| 347 | Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. <i>British Journal of Haematology</i> , 2005, 128, 783-791.  | 1.2 | 29        |
| 348 | Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. <i>Bone Marrow Transplantation</i> , 2005, 36, 183-191.   | 1.3 | 47        |
| 349 | Animal models of acute myelogenous leukaemia – development, application and future perspectives. <i>Leukemia</i> , 2005, 19, 687-706.  | 3.3 | 66        |
| 350 | High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. <i>Leukemia</i> , 2005, 19, 978-983.  | 3.3 | 46        |
| 351 | Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 1536-1542.   | 3.3 | 227       |
| 352 | Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. <i>Leukemia</i> , 2005, 19, 2030-2042.   | 3.3 | 220       |
| 353 | Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. <i>Leukemia</i> , 2005, 19, 2072-2081.        | 3.3 | 75        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 354 | Long-term results in children with AML: NOPHO-AML Study Group " report of three consecutive trials. <i>Leukemia</i> , 2005, 19, 2090-2100.   | 3.3 | 144       |
| 355 | Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2005, 74, 277-281.  | 1.1 | 4         |
| 356 | Leukemic transformation of polycythemia vera. <i>Cancer</i> , 2005, 104, 1032-1036.  | 2.0 | 79        |
| 357 | Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. <i>Cancer</i> , 2005, 104, 2717-2725.   | 2.0 | 164       |
| 358 | Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial. <i>Annals of Hematology</i> , 2005, 84, 376-382.   | 0.8 | 10        |
| 359 | A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. <i>Annals of Hematology</i> , 2005, 84, 557-564. | 0.8 | 40        |
| 360 | Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 9234-9242.   | 0.8 | 226       |
| 361 | Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3923-3931.  | 0.8 | 871       |
| 362 | ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. <i>Annals of Oncology</i> , 2005, 16, i48-i49.  | 0.6 | 5         |
| 363 | Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 482-493.  | 0.8 | 119       |
| 364 | Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. <i>Blood</i> , 2005, 106, 3768-3776.  | 0.6 | 205       |
| 365 | Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5705-5717.   | 0.8 | 324       |
| 366 | Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. <i>Annals of Oncology</i> , 2005, 16, 1366-1373.  | 0.6 | 43        |
| 367 | Classification of myeloid neoplasms: a comparative review. <i>Veterinary Clinical Pathology</i> , 2005, 34, 189-212.   | 0.3 | 52        |
| 368 | Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995). <i>Leukemia and Lymphoma</i> , 2005, 46, 55-61.  | 0.6 | 24        |
| 369 | Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity. <i>Journal of Clinical Oncology</i> , 2005, 23, 3404-3411.  | 0.8 | 143       |
| 370 | Recommendation of the use of myeloblast percentage among non-erythroid cells instead of percentage among total nucleated cells for therapeutic response assessment in acute erythroid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 683-687.  | 0.6 | 1         |
| 371 | Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. <i>Blood</i> , 2006, 107, 880-884.   | 0.6 | 83        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 372 | Immunophenotyping of Acute Leukemias Using a Quartz Crystal Microbalance and Monoclonal Antibody-Coated Magnetic Microspheres. <i>Analytical Chemistry</i> , 2006, 78, 2571-2578.   | 3.2 | 13        |
| 373 | De novo acute myeloid leukemia in adults younger than 60 years of age: Socioeconomic aspects and treatment results in a Brazilian university center. <i>Leukemia and Lymphoma</i> , 2006, 47, 1557-1564.  | 0.6 | 29        |
| 374 | The role of post-remission chemotherapy for older patients with acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 689-695.   | 0.6 | 11        |
| 375 | Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group. <i>Leukemia and Lymphoma</i> , 2006, 47, 697-706. | 0.6 | 4         |
| 376 | Estudo retrospectivo do tratamento de leucemia mielÃ³ide aguda com o transplante de medula Ã³ssea: a experiÃªncia brasileira. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2006, 28, 11.  | 0.7 | 4         |
| 377 | Ten-year Experience on Acute Promyelocytic Leukemia at Inha University Hospital. <i>The Korean Journal of Hematology</i> , 2006, 41, 289.   | 0.7 | 1         |
| 378 | Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. <i>Blood</i> , 2006, 108, 685-696.   | 0.6 | 180       |
| 379 | Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. <i>Blood</i> , 2006, 108, 63-73.               | 0.6 | 285       |
| 380 | A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. <i>Blood</i> , 2006, 108, 3262-3270.  | 0.6 | 371       |
| 381 | Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. <i>British Journal of Haematology</i> , 2006, 132, 755-769.              | 1.2 | 56        |
| 382 | Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. <i>British Journal of Haematology</i> , 2006, 134, 54-57.  | 1.2 | 50        |
| 383 | Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. <i>European Journal of Cancer Care</i> , 2006, 15, 44-50.   | 0.7 | 11        |
| 384 | ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 427-439.   | 2.3 | 43        |
| 385 | Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. <i>Leukemia Research</i> , 2006, 30, 407-413.  | 0.4 | 64        |
| 386 | The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). <i>Leukemia Research</i> , 2006, 30, 801-811.  | 0.4 | 52        |
| 387 | Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. <i>Leukemia Research</i> , 2006, 30, 813-822.   | 0.4 | 49        |
| 388 | The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. <i>Leukemia</i> , 2006, 20, 1783-1789.  | 3.3 | 117       |
| 389 | Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 73-83.   | 1.1 | 5         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 390 | Treatment of acute myelogenous leukemia with outpatient azacitidine. <i>Cancer</i> , 2006, 107, 1839-1843.  | 2.0 | 76        |
| 391 | Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 5703-5710.   | 0.8 | 162       |
| 392 | Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1712-1719.   | 0.8 | 60        |
| 393 | Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 3686-3692.   | 0.8 | 132       |
| 394 | Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2006, 24, 4499-4506.   | 0.8 | 173       |
| 395 | Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms. <i>Cancer Research</i> , 2006, 66, 6361-6369.  | 0.4 | 470       |
| 396 | Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 3904-3911.  | 0.8 | 618       |
| 397 | Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5. <i>Journal of Immunology</i> , 2006, 176, 1759-1768.   | 0.4 | 5         |
| 398 | A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. <i>British Journal of Cancer</i> , 2006, 95, 253-259.   | 2.9 | 55        |
| 399 | Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2006, 12, 5165-5173.  | 3.2 | 281       |
| 400 | Acute myeloblastic leukemia in adult patients: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2007, 18, ii47-ii48.   | 0.6 | 8         |
| 402 | Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. <i>Blood</i> , 2007, 109, 936-943.  | 0.6 | 52        |
| 403 | Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. <i>Blood</i> , 2007, 109, 5136-5142.  | 0.6 | 287       |
| 404 | Postremission therapy for acute myeloid leukemia in the first remission. <i>Leukemia and Lymphoma</i> , 2007, 48, 937-943.  | 0.6 | 6         |
| 405 | Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 72-79.   | 0.6 | 7         |
| 406 | Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. <i>Blood</i> , 2007, 109, 4164-4167.   | 0.6 | 173       |
| 407 | FLT3 Internal Tandem Duplication in Acute Myeloid Leukemia with Normal Karyotype. <i>The Korean Journal of Hematology</i> , 2007, 42, 250.  | 0.7 | 1         |
| 410 | Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOGâ€9500). <i>American Journal of Hematology</i> , 2007, 82, 1056-1062. | 2.0 | 26        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 411 | Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. <i>Cancer</i> , 2007, 110, 345-352.   | 2.0 | 113       |
| 412 | Levels of soluble HLA-I and $\beta$ 2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. <i>Leukemia</i> , 2007, 21, 480-488.                                     | 3.3 | 22        |
| 413 | Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60-75 years and older express adverse prognostic value: results from a prospective clinical trial. <i>British Journal of Haematology</i> , 2007, 136, 96-105.           | 1.2 | 59        |
| 414 | Complex karyotypes confer a poor survival in adult acute myeloid leukemia with unfavorable cytogenetic abnormalities. <i>Cancer Genetics and Cytogenetics</i> , 2007, 174, 138-146.   | 1.0 | 14        |
| 415 | A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. <i>Experimental Hematology</i> , 2007, 35, 1074-1082.                               | 0.2 | 7         |
| 416 | The expression of cytosolic phospholipase A2 and biosynthesis of leukotriene B4 in acute myeloid leukemia cells. <i>European Journal of Haematology</i> , 2007, 79, 468-476.  | 1.1 | 23        |
| 417 | CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. <i>Annals of Hematology</i> , 2007, 86, 329-337.  | 0.8 | 96        |
| 418 | Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. <i>Investigational New Drugs</i> , 2008, 26, 233-239.        | 1.2 | 45        |
| 419 | ACUTE LEUKEMIAS XII. <i>Annals of Hematology</i> , 2008, 87, 21-98.   | 0.8 | 1         |
| 420 | Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia. <i>Cancer</i> , 2008, 112, 572-580.  | 2.0 | 42        |
| 421 | Significance of age in acute myeloid leukemia patients younger than 30 years. <i>Cancer</i> , 2008, 112, 562-571.   | 2.0 | 91        |
| 422 | A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. <i>BMC Cancer</i> , 2008, 8, 195. | 1.1 | 46        |
| 423 | Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 527-540.   | 1.4 | 52        |
| 424 | Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 1446-1454.   | 3.2 | 106       |
| 425 | Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia. <i>Hematology</i> , 2008, 13, 142-146.   | 0.7 | 25        |
| 426 | Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. <i>Haematologica</i> , 2008, 93, 67-74.   | 1.7 | 188       |
| 427 | Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 3889-3895.   | 3.2 | 38        |
| 428 | A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 2756-2762.                               | 3.2 | 233       |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 429 | Endogenous Vascular Endothelial Growth Factor-C Expression Is Associated with Decreased Drug Responsiveness in Childhood Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 924-930.   | 3.2 | 22        |
| 430 | Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720. <i>Journal of Clinical Oncology</i> , 2008, 26, 4934-4939.  | 0.8 | 114       |
| 431 | Wilmsâ€™ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4595-4602.  | 0.8 | 230       |
| 432 | Acute myeloblastic leukemia in adult patients: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii58-ii59.   | 0.6 | 1         |
| 433 | Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. <i>Blood</i> , 2008, 111, 1078-1084.   | 0.6 | 156       |
| 434 | MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. <i>Blood</i> , 2008, 111, 1855-1861.   | 0.6 | 66        |
| 435 | An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2008, 112, 4193-4201.  | 0.6 | 357       |
| 436 | Pediatric Acute Promyelocytic Leukemia: All-transretinoic Acid Therapy in a Brazilian Pediatric Hospital. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 387-390.  | 0.3 | 8         |
| 437 | Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. <i>Anti-Cancer Drugs</i> , 2008, 19, 411-420.   | 0.7 | 16        |
| 438 | Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34+ Acute Myeloid Leukemia Samples. <i>Clinical Cancer Research</i> , 2009, 15, 3076-3083.   | 3.2 | 31        |
| 439 | Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience. <i>Journal of Clinical Oncology</i> , 2009, 27, 2668-2676.   | 0.8 | 90        |
| 440 | Acute myeloblastic leukemia in adult patients: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv100-iv101.   | 0.6 | 4         |
| 441 | ERG Expression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis of ERG, MN1, and BAALC Transcript Levels Using Oligonucleotide Microarrays. <i>Journal of Clinical Oncology</i> , 2009, 27, 5031-5038. | 0.8 | 119       |
| 442 | Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 4392-4397.  | 0.8 | 74        |
| 443 | Hypoplastic acute myeloid leukaemia with 7 years of complete remission by lowâ€ˆdose cytosine arabinoside therapy alone. <i>European Journal of Haematology</i> , 1995, 55, 59-60.  | 1.1 | 1         |
| 444 | Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for <i>de novo</i> acute myeloid leukemia. <i>European Journal of Haematology</i> , 1997, 58, 233-240.  | 1.1 | 7         |
| 445 | Results of riskâ€ˆadapted therapy in acute myeloid leukaemia. A longâ€ˆterm populationâ€ˆbased followâ€ˆup study. <i>European Journal of Haematology</i> , 2009, 83, 99-107.  | 1.1 | 35        |
| 446 | Prognostic significance of $\beta$ -catenin and topoisomerase II $\alpha$ in de novo acute myeloid leukemia. <i>American Journal of Hematology</i> , 2009, 84, 87-92.   | 2.0 | 29        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 447 | Blast phase of essential thrombocythemia: A single center study. <i>American Journal of Hematology</i> , 2009, 84, 641-644.   | 2.0 | 8         |
| 448 | Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. <i>American Journal of Hematology</i> , 2009, 84, 733-737.   | 2.0 | 42        |
| 449 | Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia. <i>Cancer</i> , 2009, 115, 3719-3727.   | 2.0 | 75        |
| 450 | Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. <i>International Journal of Hematology</i> , 2009, 89, 538-545.   | 0.7 | 8         |
| 451 | Treatment of children with acute promyelocytic leukemia: Results of the first North American intergroup trial INT0129. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1005-1010.   | 0.8 | 43        |
| 452 | Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. <i>Clinical and Experimental Immunology</i> , 2009, 158, 199-204.   | 1.1 | 85        |
| 453 | A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. <i>Leukemia Research</i> , 2009, 33, 1055-1061.   | 0.4 | 47        |
| 454 | Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia. <i>Leukemia Research</i> , 2009, 33, 1072-1078.   | 0.4 | 8         |
| 455 | Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. <i>Leukemia</i> , 2009, 23, 2275-2280.   | 3.3 | 63        |
| 456 | A Pilot Study of Priming With Granulocyte Macrophage Colony-Stimulating Factor Plus All-trans Retinoic Acid Combined With Remission Induction Chemotherapy in Patients With Acute Myeloid Leukemia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 227-232. | 0.6 | 1         |
| 457 | Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. <i>Haematologica</i> , 2009, 94, 54-60.  | 1.7 | 195       |
| 458 | Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 833-836.   | 1.7 | 34        |
| 459 | P-glycoprotein inhibition using valsopodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. <i>Blood</i> , 2010, 116, 1413-1421.  | 0.6 | 113       |
| 460 | Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i> , 2010, 116, 3751-3757.  | 0.6 | 348       |
| 462 | Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.   | 0.6 | 2,963     |
| 463 | Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis. <i>Cancer</i> , 2010, 116, 5012-5021.  | 2.0 | 99        |
| 464 | The incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1997-2001: A survey of patients aged >=65 years. <i>Cancer Epidemiology</i> , 2010, 34, 24-28.   | 0.8 | 3         |
| 465 | Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 48-58.    | 1.2 | 26        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 466 | Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. <i>British Journal of Haematology</i> , 2010, 149, 399-409.   | 1.2 | 52        |
| 467 | Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003. <i>British Journal of Haematology</i> , 2010, 151, 447-459.  | 1.2 | 47        |
| 468 | BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis. <i>International Journal of Laboratory Hematology</i> , 2010, 32, 197-205.  | 0.7 | 29        |
| 470 | Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1766-1771. | 0.8 | 187       |
| 471 | Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2010, 28, 2682-2689.   | 0.8 | 190       |
| 472 | Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2010, 28, 285-291.   | 0.8 | 70        |
| 473 | Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. <i>Epigenetics</i> , 2010, 5, 590-600.  | 1.3 | 42        |
| 474 | A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule. <i>Hematology</i> , 2010, 15, 125-131.   | 0.7 | 3         |
| 475 | Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated With a Higher Incidence of Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 2591-2597.         | 0.8 | 62        |
| 476 | Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A. <i>Journal of Clinical Oncology</i> , 2010, 28, 4642-4648.         | 0.8 | 205       |
| 477 | Acute leukemia presenting with blasts first found in the cerebrospinal fluid but not in the peripheral blood. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 1252-1255.   | 0.8 | 7         |
| 478 | Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 3717-3723.  | 0.8 | 189       |
| 479 | A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. <i>Leukemia and Lymphoma</i> , 2010, 51, 252-260.            | 0.6 | 85        |
| 480 | Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3890-3898.   | 0.8 | 217       |
| 481 | TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1373-1381.   | 0.8 | 291       |
| 482 | Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia. <i>Einstein (Sao Paulo, Brazil)</i> , 2011, 9, 190-195.  | 0.3 | 1         |
| 483 | Classification of Acute Leukemia. , 0, , .   |     | 7         |
| 484 | Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. , 2011, , CD008238.   |     | 6         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 485 | Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Haematologica</i> , 2011, 96, 1488-1495. | 1.7 | 20        |
| 486 | The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. <i>Blood</i> , 2011, 117, 2137-2145.   | 0.6 | 392       |
| 487 | Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). <i>Blood</i> , 2011, 118, 5409-5415.   | 0.6 | 56        |
| 488 | Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2011, 152, 623-630.   | 1.2 | 9         |
| 489 | Primary refractory acute myeloid leukaemia " in search of better definitions and therapies. <i>British Journal of Haematology</i> , 2011, 155, 413-419.   | 1.2 | 30        |
| 490 | Translocation t(1;16)(p31;q24) rearranging CBFA2T3 is specific for acute erythroid leukemia. <i>Leukemia</i> , 2011, 25, 1510-1512.   | 3.3 | 16        |
| 491 | Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. <i>Leukemia</i> , 2011, 25, 1423-1432.   | 3.3 | 47        |
| 492 | A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy. <i>Annals of Hematology</i> , 2011, 90, 1283-1291.   | 0.8 | 4         |
| 493 | CNS irradiation in pediatric acute myeloid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. <i>Pediatric Blood and Cancer</i> , 2011, 57, 986-992.   | 0.8 | 25        |
| 494 | Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 2145-2155.   | 2.0 | 91        |
| 495 | Minimally differentiated acute myeloid leukemia (FAB AML-M0): Prognostic factors and treatment effects on survival" A retrospective study of 42 adult cases. <i>Leukemia Research</i> , 2011, 35, 1027-1031.  | 0.4 | 7         |
| 496 | Expression of cyclin A and bone morphogenetic protein receptors and response to induction therapy in patients with acute leukemias. <i>Leukemia and Lymphoma</i> , 2011, 52, 2336-2341.   | 0.6 | 2         |
| 497 | Pulmonary radiological findings in patients with acute myeloid leukemia and their relation to chemotherapy and prognosis: a single center retrospective study. <i>Turkish Journal of Haematology</i> , 2011, 29, 217-22.  | 0.2 | 6         |
| 498 | The Incidence and Survival of Acute de novo Leukemias in Estonia and in a Well-Defined Region of Western Sweden during 1997-2001: A Survey of Patients Aged 16-64 Years. <i>Acta Haematologica</i> , 2011, 126, 176-185.  | 0.7 | 3         |
| 499 | Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. <i>Leukemia</i> , 2011, 25, 800-807.  | 3.3 | 24        |
| 500 | ACUTE PROMYELOCYTIC LEUKEMIA: AN EXPERIENCE ON 95 GREEK PATIENTS TREATED IN THE ALL-TRANS-RETINOIC ACID ERA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011053.  | 0.5 | 13        |
| 501 | Clinical Implications of Non-A-Type NPM1 and FLT3 Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2012, 127, 63-71.   | 0.7 | 19        |
| 502 | Institutional Experience With Clofarabine and Cytarabine in Relapsed Pediatric Acute Myeloid Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e17-e21.   | 0.3 | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 503 | Retrospective analysis of 119 cases of pediatric acute promyelocytic leukemia: Comparisons of four treatment regimes. <i>Experimental and Therapeutic Medicine</i> , 2012, 4, 93-98.  | 0.8 | 6         |
| 504 | Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF- $\beta$ 2 in acute myeloid leukemia. <i>Oncology Letters</i> , 2012, 3, 1119-1123.  | 0.8 | 63        |
| 505 | The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. <i>Haematologica</i> , 2012, 97, 21-29.                              | 1.7 | 78        |
| 506 | Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. <i>Blood</i> , 2012, 120, 3187-3205.  | 0.6 | 451       |
| 507 | Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 4515-4523. | 0.8 | 363       |
| 508 | <i>Hematological Cancers.</i> , 2012, , 279-325.  |     | 0         |
| 509 | Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 1096-1104.  | 5.1 | 58        |
| 510 | Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 578-582.   | 2.5 | 9         |
| 511 | Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. <i>Leukemia</i> , 2012, 26, 654-661.   | 3.3 | 60        |
| 512 | Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). <i>Medical Oncology</i> , 2012, 29, 2095-2101.   | 1.2 | 19        |
| 513 | Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. <i>The Cochrane Library</i> , 2012, , CD008238.  | 1.5 | 28        |
| 514 | <i>Disorders of Bone Marrow.</i> , 2012, , 260-327.   |     | 7         |
| 515 | Overexpression of Lung Resistance-Related Protein and P-Glycoprotein and Response to Induction Chemotherapy in Acute Myelogenous Leukemia. <i>Hematology Reports</i> , 2012, 4, e18.  | 0.3 | 12        |
| 516 | Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 742-750.                           | 0.8 | 244       |
| 517 | Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 776-784.            | 1.1 | 32        |
| 518 | Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 283-294.      | 0.7 | 13        |
| 519 | The biological characteristics of adult CD34+ acute promyelocytic leukemia. <i>Medical Oncology</i> , 2012, 29, 1119-1126.  | 1.2 | 12        |
| 520 | Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 991-997. | 1.3 | 41        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 521 | Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia. <i>Leukemia Research</i> , 2012, 36, 570-574.  | 0.4 | 8         |
| 522 | Phase <sc>II</sc> study of doseâ€modified busulfan by realâ€time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy. <i>Cancer Science</i> , 2012, 103, 1688-1694.   | 1.7 | 10        |
| 523 | Smoking adversely affects survival in acute myeloid leukemia patients. <i>International Journal of Cancer</i> , 2012, 130, 1451-1458.  | 2.3 | 20        |
| 524 | Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 145-152.  | 0.6 | 36        |
| 525 | The recipient CXCL10 +1642C>G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation. <i>Clinical Immunology</i> , 2013, 146, 104-111.   | 1.4 | 14        |
| 526 | Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 46-53.  | 0.3 | 3         |
| 527 | Anti-leukemia activity of PVP-coated silver nanoparticles via generation of reactive oxygen species and release of silver ions. <i>Biomaterials</i> , 2013, 34, 7884-7894.   | 5.7 | 255       |
| 528 | Epigenetic Alterations in Oncogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, v-vii.  | 0.8 | 10        |
| 529 | Increased Th22 cells as well as Th17 cells in patients with adult T-cell acute lymphoblastic leukemia. <i>Clinica Chimica Acta</i> , 2013, 426, 108-113.   | 0.5 | 20        |
| 530 | Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. <i>Blood</i> , 2013, 122, 37-43.   | 0.6 | 151       |
| 531 | Skeletal morbidity is strongly associated with poor prognosis in adult acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 117-122.   | 0.6 | 1         |
| 532 | New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 385-401.  | 1.5 | 13        |
| 533 | Classification of the Acute Leukemias: Cytochemical and Morphologic Considerations. , 2013, , 213-239.   |     | 1         |
| 534 | Diagnosis and Treatment of Childhood Acute Myeloid Leukemia. , 2013, , 355-373.  |     | 1         |
| 535 | Sequential population-based studies over 25Âyears on the incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1982â€2006: a survey of patients aged â‰¥65Âyears. <i>Medical Oncology</i> , 2013, 30, 487.                            | 1.2 | 1         |
| 536 | Epigenetic Therapies in MDS and AML. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, 253-283.  | 0.8 | 52        |
| 538 | A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2. <i>Clinical Cancer Research</i> , 2013, 19, 1873-1883.   | 3.2 | 32        |
| 539 | A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. <i>Leukemia and Lymphoma</i> , 2013, 54, 760-766. | 0.6 | 43        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 540 | Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: <i>miR-155</i> Upregulation Independently Identifies High-Risk Patients. <i>Journal of Clinical Oncology</i> , 2013, 31, 2086-2093.   | 0.8 | 165       |
| 541 | Hsp27: A novel therapeutic target for pediatric M4/M5 acute myeloid leukemia. <i>Oncology Reports</i> , 2013, 29, 1459-1466.   | 1.2 | 21        |
| 542 | Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). <i>Blood</i> , 2013, 121, 170-177.   | 0.6 | 164       |
| 543 | Aberrant T Helper 17 Cells and Related Cytokines in Bone Marrow Microenvironment of Patients with Acute Myeloid Leukemia. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-10.   | 3.3 | 11        |
| 544 | Acute Leukemia Clinical Presentation. , 2013, , .  |     | 3         |
| 545 | Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1332-1336.  | 0.6 | 6         |
| 546 | Efficacy and tolerability of treatment with azacitidine for 5Âdays in elderly patients with acute myeloid leukemia. <i>Cancer Medicine</i> , 2014, 3, 1570-1578.   | 1.3 | 15        |
| 547 | Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. <i>European Journal of Haematology</i> , 2014, 93, 54-62.   | 1.1 | 11        |
| 548 | Recombinant interleukinâ€2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808. <i>Cancer</i> , 2014, 120, 1010-1017.   | 2.0 | 25        |
| 549 | Frequency and prognostic significant of CYP3A4-A290G polymorphism in acute myeloid leukemia. <i>Journal of Advanced Research</i> , 2014, 5, 657-661.   | 4.4 | 11        |
| 550 | Glutathione S-transferase genotypes and numerical chromosomal aberrations in myeloid neoplasms. <i>Comparative Clinical Pathology</i> , 2014, 23, 1023-1029.   | 0.3 | 1         |
| 551 | Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2014, 93, 193-202.              | 0.8 | 7         |
| 552 | Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. <i>American Journal of Hematology</i> , 2014, 89, 410-416.  | 2.0 | 91        |
| 553 | (6)-Gingerolinduced myeloid leukemia cell death is initiated by reactive oxygen species and activation of miR-27b expression. <i>Free Radical Biology and Medicine</i> , 2014, 68, 288-301.  | 1.3 | 49        |
| 554 | Clofarabine/cyclophosphamide for debulking before stem cell transplantation. <i>European Journal of Clinical Investigation</i> , 2014, 44, 775-783.  | 1.7 | 3         |
| 555 | Treatment with FLT3 inhibitor in patients with <i>FLT3</i> mutated acute myeloid leukemia is associated with development of secondary <i>FLT3</i> tyrosine kinase domain mutations. <i>Cancer</i> , 2014, 120, 2142-2149.  | 2.0 | 107       |
| 556 | High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 219-228.                                     | 0.8 | 145       |
| 557 | Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1399-1406. | 2.0 | 10        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 558 | Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. <i>Annals of Hematology</i> , 2015, 94, 1327-1336.  | 0.8 | 54        |
| 559 | Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length. <i>Blood Cancer Journal</i> , 2015, 5, e336-e336.  | 2.8 | 59        |
| 560 | Study of prognostic significance of marrow angiogenesis assessment in patients with de novo acute leukemia. <i>Hematology</i> , 2015, 20, 504-510.   | 0.7 | 7         |
| 561 | Reduced-Intensity Conditioning Combined with 188Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1754-1760.                      | 2.0 | 12        |
| 562 | Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 3365-3369.  | 0.6 | 2         |
| 563 | Risk factors for tumor lysis syndrome in childhood acute myeloid leukemia treated with a uniform protocol without rasburicase prophylaxis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2193-2195.   | 0.6 | 3         |
| 564 | Prognostic Factors, Response to Treatment, and Survival in Patients With Chronic Myeloid Leukemia in Blast Phase: A Single-Institution Survey. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 778-784.   | 0.2 | 13        |
| 565 | Higher percentage of CD34 + CD38 <sup>+</sup> cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 622-629.   | 0.6 | 9         |
| 566 | A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. <i>British Journal of Haematology</i> , 2015, 169, 694-700.  | 1.2 | 90        |
| 567 | Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML – Results from Study AML-BFM 2004. <i>Klinische Padiatrie</i> , 2015, 227, 116-122.   | 0.2 | 2         |
| 568 | Adult Acute Myeloid Leukemia – A Possible Relation to Disease Invasion and the Impact of Independent Prognostic Markers Associated with Survival Outcome. , 0, , .   |     | 0         |
| 569 | Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0146614.   | 1.1 | 44        |
| 570 | Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR. <i>Bone Marrow Transplantation</i> , 2016, 51, 921-927.  | 1.3 | 8         |
| 571 | Response Assessment Criteria and Their Applications in Lymphoma: Part 1. <i>Journal of Nuclear Medicine</i> , 2016, 57, 928-935.   | 2.8 | 21        |
| 572 | Digital gene expression profiling analysis of childhood acute lymphoblastic leukemia. <i>Molecular Medicine Reports</i> , 2016, 13, 4321-4328.   | 1.1 | 5         |
| 573 | Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2016, 6, e387-e387.   | 2.8 | 14        |
| 574 | Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. <i>Leukemia Research</i> , 2016, 40, 1-9.  | 0.4 | 29        |
| 575 | Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 584-588. | 2.0 | 45        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 576 | Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 305-315. | 1.2 | 19        |
| 577 | Acute myeloid leukemia – strategies and challenges for targeting oncogenic Hedgehog/GLI signaling. <i>Cell Communication and Signaling</i> , 2017, 15, 8.   | 2.7 | 47        |
| 578 | Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. <i>Blood</i> , 2017, 129, 3314-3321.   | 0.6 | 64        |
| 579 | Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004. <i>Leukemia</i> , 2017, 31, 2807-2814.   | 3.3 | 15        |
| 580 | Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1391-1400.  | 1.7 | 28        |
| 581 | Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4641-E4647.  | 3.3 | 36        |
| 583 | Aberrant NLRP3 inflammasome associated with aryl hydrocarbon receptor potentially contributes to the imbalance of T helper cells in patients with acute myeloid leukemia. <i>Oncology Letters</i> , 2017, 14, 7031-7044.  | 0.8 | 15        |
| 584 | Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of acute myeloid leukemia: A prospective, randomized study. <i>American Journal of Hematology</i> , 2017, 92, 12-17.  | 2.0 | 5         |
| 585 | The Prevalance of Sensori-Neural Hearing Loss and Ototoxicity in Acute Myeloid Leukemia Patients. <i>Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research</i> , 2017, 11, .   | 0.1 | 0         |
| 586 | ACUTE PROMYELOCYTIC LEUKEMIA IN CHILDREN: A SINGLE CENTRE EXPERIENCE FROM TURKEY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, e2018045.  | 0.5 | 6         |
| 587 | Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. <i>Leukemia</i> , 2018, 32, 2167-2177.   | 3.3 | 155       |
| 588 | Classification of the Acute Leukemias: Cytochemical and Morphologic Considerations. , 2018, , 197-236.  |     | 0         |
| 589 | Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 121-128.  | 0.6 | 1         |
| 590 | Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA. <i>Blood Advances</i> , 2018, 2, 2724-2731.  | 2.5 | 46        |
| 591 | Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. <i>Blood Advances</i> , 2018, 2, 1645-1650.   | 2.5 | 85        |
| 592 | Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. <i>Annals of Hematology</i> , 2018, 97, 1785-1795.                      | 0.8 | 4         |
| 593 | Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-TNF Receptor-2 Pathway. <i>Frontiers in Immunology</i> , 2018, 9, 1274.   | 2.2 | 43        |
| 594 | Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1136-1141.  | 2.0 | 95        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 595 | Survival analysis of adult patients with <scp>ALL</scp> in Mexico City: first report from the Acute Leukemia Workgroup (<scp>ALWG</scp>) (<scp>GTLA</scp>). <i>Cancer Medicine</i> , 2018, 7, 2423-2433.  | 1.3 | 14        |
| 596 | Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2226-2237.  | 1.9 | 39        |
| 597 | Increased Survival for Children With Acute Myeloid Leukemia Results From Improved Postrelapse Treatment. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 541-547.   | 0.3 | 4         |
| 598 | Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e205-e212.            | 0.2 | 4         |
| 599 | Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. <i>Modern Pathology</i> , 2019, 32, 1373-1385. | 2.9 | 25        |
| 600 | Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low- to middle-income country. <i>Annals of Hematology</i> , 2019, 98, 1403-1411.   | 0.8 | 17        |
| 601 | Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance) Tj ETQq0 0 0 rBT /Overlock 10 Tff  | 2.5 | 11        |
| 602 | The stem cell- specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia. <i>Blood Advances</i> , 2019, 3, 4252-4263.  | 2.5 | 22        |
| 603 | Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 729-734.  | 0.2 | 6         |
| 604 | Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study). <i>Mycoses</i> , 2020, 63, 1094-1100.   | 1.8 | 6         |
| 605 | Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. <i>Blood Advances</i> , 2020, 4, 5146-5156.  | 2.5 | 5         |
| 606 | Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. <i>Blood Advances</i> , 2020, 4, 1942-1949.  | 2.5 | 49        |
| 607 | <p></p>Protective Effects of Cytomegalovirus DNA Copies <math>\leq 1000</math>/mL for AML Patients in Complete Remission After Single Cord Blood Transplantation<p></p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 373-383.               | 1.1 | 3         |
| 608 | Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase <scp>III</scp> study. <i>American Journal of Hematology</i> , 2020, 95, 749-758.                  | 2.0 | 12        |
| 609 | Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment. <i>Advances in Therapy</i> , 2020, 37, 2288-2302.                   | 1.3 | 1         |
| 610 | The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 470-480.   | 1.3 | 3         |
| 611 | Molecular methods for measurable residual disease in acute myeloid leukemia: where are we and where are we going?. <i>Journal of Hematopathology</i> , 2021, 14, 3-14.  | 0.2 | 0         |
| 612 | Semaphorin 4D is a potential biomarker in pediatric leukemia and promotes leukemogenesis by activating PI3K/AKT and ERK signaling pathways. <i>Oncology Reports</i> , 2021, 45, .   | 1.2 | 29        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 613 | Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14199.   | 0.8 | 4         |
| 614 | Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2358-2370.   | 3.3 | 31        |
| 615 | Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, 34, 1358-1366.   | 2.9 | 8         |
| 616 | AHR signaling pathway reshapes the metabolism of AML/MDS cells and potentially leads to cytarabine resistance. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 492-500.  | 0.9 | 5         |
| 617 | Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. <i>Cancers</i> , 2021, 13, 2336.  | 1.7 | 30        |
| 618 | Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. <i>Blood</i> , 2022, 139, 1785-1793.  | 0.6 | 28        |
| 619 | The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. <i>Blood Reviews</i> , 2021, 48, 100806.   | 2.8 | 14        |
| 620 | Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study. <i>Leukemia Research</i> , 2021, 108, 106627.   | 0.4 | 6         |
| 621 | <i>Cancer Cytogenetics.</i> , 1999, , 345-420.   |     | 2         |
| 622 | AML in the Elderly: a Biologically Distinct Disease in which MDR1 Expression and Unfavorable Cytogenetics Contribute to Poor Clinical Response. <i>Studies of the Southwest Oncology Group. Hamatologie Und Bluttransfusion</i> , 1998, , 413-421.   | 0.0 | 2         |
| 623 | In Acute Myeloid Leukemia only the Coexpression of at Least Two Proteins Including P-Glycoprotein, the Multidrug Resistance-Related Protein MRP, bcl-2, Mutant p53 and Heat-Shock Protein 27 is Predictive for the Response to Induction Chemotherapy. <i>Hamatologie Und Bluttransfusion</i> , 1998, , 444-453. | 0.0 | 10        |
| 624 | Immunophenotype of Acute Myeloid Leukemia: Correlation with Morphological Characteristics and Therapy Response. <i>Recent Results in Cancer Research</i> , 1993, 131, 381-392.   | 1.8 | 8         |
| 625 | <i>Leukämien und Lymphome.</i> , 2018, , 267-357.  |     | 1         |
| 626 | <i>Leukocytic Disorders.</i> , 2011, , 601-655.  |     | 4         |
| 627 | Short-Term Intensive Consolidation Therapy After All-Trans Retinoic Acid in Acute Promyelocytic Leukemia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 294-297.  | 0.6 | 2         |
| 628 | Minimally differentiated acute myeloid leukaemia revealed by specific cutaneous lesions. <i>British Journal of Dermatology</i> , 1996, 135, 119-123.   | 1.4 | 3         |
| 629 | Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22). <i>Blood</i> , 1997, 90, 1643-1648.   | 0.6 | 5         |
| 630 | Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients. <i>Blood</i> , 1997, 90, 2465-2470.  | 0.6 | 8         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 631 | A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031). <i>Blood</i> , 1998, 91, 3607-3615.     | 0.6 | 6         |
| 632 | Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 1910-1917.  | 0.6 | 3         |
| 633 | Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar). <i>Blood</i> , 1999, 93, 787-795.  | 0.6 | 35        |
| 635 | Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. <i>Blood</i> , 2000, 95, 2637-2644.  | 0.6 | 14        |
| 636 | Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. <i>Blood</i> , 2000, 96, 4075-4083.                | 0.6 | 31        |
| 638 | High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0124241.   | 1.1 | 33        |
| 639 | The Profile of T Helper Subsets in Bone Marrow Microenvironment Is Distinct for Different Stages of Acute Myeloid Leukemia Patients and Chemotherapy Partly Ameliorates These Variations. <i>PLoS ONE</i> , 2015, 10, e0131761.         | 1.1 | 35        |
| 640 | Study of Survivin and X-Linked Inhibitor of Apoptosis Protein (XIAP) Genes in Acute Myeloid Leukemia (AML). <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2012, 18, 1-10. | 1.2 | 21        |
| 642 | The Myelodysplastic Syndromes. <i>Oncologist</i> , 1997, 2, 28-39.  | 1.9 | 7         |
| 643 | HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 3623-3634.   | 0.8 | 7         |
| 644 | Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. <i>Oncotarget</i> , 2016, 7, 12840-12856.   | 0.8 | 63        |
| 645 | Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. <i>Haematologica</i> , 2010, 95, 928-935.   | 1.7 | 63        |
| 646 | Diagnostic and prognostic value of plasma level of microRNA-92a in acute myeloid leukemia. <i>American Journal of Molecular Biology</i> , 2014, 04, 1-10.   | 0.1 | 4         |
| 647 | How to Establish Acute Myeloid Leukemia Xenograft Models Using Immunodeficient Mice. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 7057-7063.   | 0.5 | 9         |
| 648 | Recent Advances in the Management of Pediatric Acute Myeloid Leukemia—Report of the Hungarian Pediatric Oncology-Hematology Group. <i>Cancers</i> , 2021, 13, 5078.   | 1.7 | 1         |
| 649 | Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. <i>Blood</i> , 2000, 95, 72-77.  | 0.6 | 2         |
| 650 | Acute Leukemia and Myelodysplastic Syndromes. <i>Diagnostic Pathology</i> , 2000, , 193-221.  | 0.0 | 0         |
| 651 | Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. <i>Blood</i> , 2000, 96, 3948-3952.   | 0.6 | 60        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 652 | A Landmark Analysis of Survival by Response Category in Elderly Patients with Acute Myeloblastic Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 2001, , 644-646.                                       | 0.0 | 0         |
| 653 | Recent Genetic Studies of Adult Patients with Acute Myeloid Leukemia Performed by the Cancer and Leukemia Group B. <i>Hamatologie Und Bluttransfusion</i> , 2001, , 449-456.                               | 0.0 | 0         |
| 654 | Risk-Adapted Therapy and Randomization in Children with AML: Preliminary Results of Study AML-BFM 93. <i>Hamatologie Und Bluttransfusion</i> , 2001, , 519-524.  | 0.0 | 0         |
| 655 | Are there Two Main Categories of de Novo Acute Myeloid Leukemias with a Normal Karyotype?. <i>Hamatologie Und Bluttransfusion</i> , 2001, , 54-60.   | 0.0 | 0         |
| 656 | Evidence of Angiogenesis in Acute Myeloid Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 2001, , 152-159.  | 0.0 | 0         |
| 657 | Myelodysplastisches Syndrom und akute myeloische Leukämie. , 2002, , 389-419.  |     | 0         |
| 658 | Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms of the Bone Marrow. <i>Archives of Pathology and Laboratory Medicine</i> , 2002, 126, 1050-1056.                      | 1.2 | 13        |
| 659 | Akute myeloische Leukämien. , 2003, , 312-350.   |     | 0         |
| 660 | Phase I Clinical Evaluation of Topotecan Combined with Idarubicin and Cytarabine in Patients with Refractory or Relapsed Acute Myeloid Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 2003, , 412-417. | 0.0 | 0         |
| 661 | Acute Myeloid Leukemia in Elderly Patients: Prognostic Value of Bone Marrow Aspirate on 14th Day of Induction Treatment. <i>Hamatologie Und Bluttransfusion</i> , 2003, , 321-326.                         | 0.0 | 0         |
| 662 | Cytogenetics for Treatment Stratification in De Novo Adult Acute Myeloid Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 2003, , 366-376.   | 0.0 | 0         |
| 665 | Application of Monoclonal Antibodies to the Diagnosis and Classification of Acute Leukemias. , 2004, , 41-59.  |     | 0         |
| 666 | çŠ-ãçCE«ãéÈ;Èâ™™è...«ç: Nippon Juishikai Zasshi Journal of the Japan Veterinary Medical Association, 2005, 58, 434-435.  | 0.0 | 0         |
| 667 | Akute myeloische Leukämie. , 2006, , 5379-5403.  |     | 0         |
| 669 | Prognostic Significance of CEBPA Mutations and BAALC Expression in Acute Myeloid Leukemia Patients with Normal Karyotype. <i>Electronic Journal of General Medicine</i> , 2010, 7, .                       | 0.3 | 0         |
| 670 | Acute Leukemias of Ambiguous Lineage. , 2011, , 640-645.   |     | 1         |
| 673 | High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. <i>Blood</i> , 1991, 77, 1429-1435.                              | 0.6 | 25        |
| 674 | Acute Myeloid Leukaemia. , 1992, , 107-121.  |     | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 676 | Diagnostic Criteria of Leukemias in Domestic Animals. Nippon Juishikai Zasshi Journal of the Japan Veterinary Medical Association, 1994, 47, 1-8.                    | 0.0 | 0         |
| 677 | Akute Leukämien. , 1995, , 549-566.  |     | 0         |
| 678 | Akute myeloische Leukämie. , 1995, , 111-123.  |     | 0         |
| 679 | Distribution of Cells with a "Stem Cell Like" Immunophenotype in Acute Leukemia. Hamatologie Und Bluttransfusion, 1996, , 506-513.                                   | 0.0 | 0         |
| 681 | Clinicopathology of 15 Cases of Feline Acute Leukemias. Nippon Juishikai Zasshi Journal of the Japan Veterinary Medical Association, 1997, 50, 38-42.                | 0.0 | 0         |
| 682 | Cytomorphology and Clinical Outcome in 80 Patients with AML M4Eo and Inversion 16. Hamatologie Und Bluttransfusion, 1997, , 288-293.                                 | 0.0 | 0         |
| 683 | Detection of Minimal Residual Disease in Cytogenetically Defined Prognostic Subgroups of AML. Hamatologie Und Bluttransfusion, 1997, , 333-338.                      | 0.0 | 0         |
| 684 | Akute myeloische Leukämie im Kindesalter. , 1997, , 1639-1664.   |     | 0         |
| 685 | Akute myeloische Leukämie. , 1998, , 165-179.  |     | 0         |
| 686 | Intermediate Dose Cytarabine and Idarubicin for Salvage Therapy of Acute Myeloid Leukemia. Hamatologie Und Bluttransfusion, 1998, , 936-942.                         | 0.0 | 0         |
| 687 | Akute Leukämien. , 1999, , 958-966.  |     | 0         |
| 688 | Akute myeloische Leukämie im Kindesalter. , 1999, , 687-698.   |     | 0         |
| 689 | Milz. , 1999, , 549-657.   |     | 1         |
| 691 | Treatment of Childhood Acute Myeloid Leukemia in Bulgaria. Folia Medica, 2018, 60, 234-240.  | 0.2 | 2         |
| 694 | Akute myeloische Leukämie. , 0, , 239-250.   |     | 0         |
| 695 | Special Diagnostics. , 2008, , 39-64.  |     | 0         |
| 696 | Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups. Asian Pacific Journal of Cancer Prevention, 2016, 17, 5251-5256. | 0.5 | 5         |
| 700 | Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. Cancers, 2022, 14, 616.                           | 1.7 | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 701 | Clinicopathological study of acute myeloid leukemia in a tertiary care hospital. International Journal of Health Sciences, 0, , 3070-3077.                              | 0.0 | 1         |
| 702 | Acute Leukaemia: Cytology, Cytochemistry and the FAB Classification. , 0, , 1-56.   |     | 1         |
| 703 | Autologous Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. , 0, , 1221-1237.   |     | 0         |
| 706 | High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. Blood Advances, 2022, 6, 5570-5581.                    | 2.5 | 8         |
| 708 | Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia, 2023, 37, 788-798. | 3.3 | 13        |
| 709 | Quatitative Platelet Parameters In Normal and Cancer Patients -A Comparative Analysis. , 2023, , .  |     | 0         |